Related Content
Oct. 30, 2025 — Recor Medical and its parent company, Otsuka Medical Devices presented the results from two clinical ...
November 03, 2025
Nov. 1, 2024 — Recor Medical, Inc. and its parent company, Otsuka Medical Devices Co. recently announced U.S. Centers ...
November 08, 2024
November 20, 2023 — A groundbreaking advancement in the treatment of patients with uncontrolled hypertension (HTN) has ...
November 20, 2023
November 15, 2023 — Recor Medical, Inc. and its parent company, Otsuka Medical Devices Co., Ltd. announced the first ...
November 15, 2023
January 9, 2023 — ReCor Medical, Inc. and its parent company, Otsuka Medical Devices Co., Ltd. announced the appointment ...
January 09, 2023
September 26, 2022 — ReCor Medical, Inc., a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd., announced the ...
September 26, 2022
Feature | Hypertension| By Dave Fornell, Editor
May 16, 2021 — Two months after undergoing renal denervation (RDN) with the ReCor Paradise renal denervation system ...
May 16, 2021
May 31, 2018 – ReCor Medical announced that the RADIANCE-HTN SOLO study met its primary efficacy endpoint and ...
May 30, 2018
January 28, 2014 — ReCor Medical advanced its Paradise System for renal denervation (RDN) for treatment resistant ...
January 28, 2014
Feature | Dave Fornell
One of the exciting new frontiers for interventional cardiology is the use of renal denervation therapy to treat ...
July 30, 2013